Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7047
pubmed:dateCreated
2005-7-7
pubmed:abstractText
Systematic analyses of cancer genomes promise to unveil patterns of genetic alterations linked to the genesis and spread of human cancers. High-density single-nucleotide polymorphism (SNP) arrays enable detailed and genome-wide identification of both loss-of-heterozygosity events and copy-number alterations in cancer. Here, by integrating SNP array-based genetic maps with gene expression signatures derived from NCI60 cell lines, we identified the melanocyte master regulator MITF (microphthalmia-associated transcription factor) as the target of a novel melanoma amplification. We found that MITF amplification was more prevalent in metastatic disease and correlated with decreased overall patient survival. BRAF mutation and p16 inactivation accompanied MITF amplification in melanoma cell lines. Ectopic MITF expression in conjunction with the BRAF(V600E) mutant transformed primary human melanocytes, and thus MITF can function as a melanoma oncogene. Reduction of MITF activity sensitizes melanoma cells to chemotherapeutic agents. Targeting MITF in combination with BRAF or cyclin-dependent kinase inhibitors may offer a rational therapeutic avenue into melanoma, a highly chemotherapy-resistant neoplasm. Together, these data suggest that MITF represents a distinct class of 'lineage survival' or 'lineage addiction' oncogenes required for both tissue-specific cancer development and tumour progression.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1476-4687
pubmed:author
pubmed:issnType
Electronic
pubmed:day
7
pubmed:volume
436
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
117-22
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:16001072-Cell Line, Tumor, pubmed-meshheading:16001072-Cell Lineage, pubmed-meshheading:16001072-Cell Survival, pubmed-meshheading:16001072-Chromosomes, Human, Pair 3, pubmed-meshheading:16001072-DNA-Binding Proteins, pubmed-meshheading:16001072-Disease Progression, pubmed-meshheading:16001072-Gene Amplification, pubmed-meshheading:16001072-Gene Dosage, pubmed-meshheading:16001072-Gene Expression Regulation, Neoplastic, pubmed-meshheading:16001072-Genomics, pubmed-meshheading:16001072-Humans, pubmed-meshheading:16001072-In Situ Hybridization, Fluorescence, pubmed-meshheading:16001072-Melanoma, pubmed-meshheading:16001072-Microphthalmia-Associated Transcription Factor, pubmed-meshheading:16001072-Oncogenes, pubmed-meshheading:16001072-Polymerase Chain Reaction, pubmed-meshheading:16001072-Polymorphism, Single Nucleotide, pubmed-meshheading:16001072-Transcription Factors
pubmed:year
2005
pubmed:articleTitle
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.
pubmed:affiliation
Department of Medical Oncology, and Melanoma Program in Medical Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural